Posted to the Scrying Biotech website on August 31st, my first purchase of $13,994 was made on September 4th for $8.88 a share. Over the next 3 days, the stock rose over 32%. I sold shares each day for a total profit of $4,235. Here was my strategy taken directly from the last paragraph of the "I'm In" page.
"I'm looking for a 30% climb and will be out upon reaching that target. I'm mindful, however, that publication of positive Phase I results in a prestigious scientific review such as the New England Journal of Medicine, could see the stock double in value over night. Nonetheless, I'll take profits as they present themselves."
That's a good and auspicious start. Let's hope we do as well moving forward. It should be noted that I took out a second position in ACTCD with the profits only and will hold through November 6th or a 30% gain - whichever comes first. This is not however part of the Scrying Record. Those trades are found only under the "I'm In" tab.
In 2013, after less than six months in biotechnology investing, I began applying thaumaturgical analysis in addition to all of the traditional and sundry due diligence techniques. Here's a graphical representation of how this created separation from the standard indices in 2013.
In 2014, I ignored my previous success, in part, because almost every reading I did on a stock turned up as negative as the overall sector performance played out to be. Additionally, I was determined to be a better analyst, better writer and better researcher. The following graphic demonstrates how losing my way cost me money. Note too, however, that once I shifted my thought process back to what works and left Seeking Alpha, my performance steeply ascends upward. These graphics are taken from my brokerage account analytical tools. Here's my year to date performance on a cost basis.
Overall, I'm still up 48.81% on the year even with several notable setbacks.
At this time, I'm back to a thaumaturgical first approach and my brokerage account is benefiting from that choice.
Always be well...
I always buy on irrational pullbacks.
If you were here on August 31st, you knew not to hold onto Amarin shares any longer. Simply click on the "Free Content" tab and then on Amarin (AMRN) and you'll clearly see an inauspicious omen in the investor sector of the "Present" container. Here's a look at the 3-Month Chart.
You'll note that the 31.5% run-up began with my article in Seeking Alpha published July 21st and ended with this press release dated yesterday, September 12th.
Not only did I predict the ultimate outcome of the SPA rescission appeal, but I gave you a look ahead into Q4 which will feature two distinctly different realities for investors and corporate leadership.
John Thero will continue to decry the injustice of Amarin's regulatory predicament, but investors will move on with a clear vision of the future. It is for this reason that I purchased 1,480 shares at $1.41 today. And I expect to make a healthy return of 15% or more by November 15th.
Vascepa sales will climb steeply in the fall months ahead giving the company a new vision of a prosperous future. Meanwhile, John Thero will make no small amount of noise on the judicial front which will cause investors to once again feel confident and buy in.
Always be well.
As many of you know, I've been writing articles on Seeking Alpha now for several years. My focus has been on the biotechnology sector and that will continue to be the case moving forward. I have, however, decided to stop supplying content to that website as it took me further from my divinatory roots where I had so much earlier success.
This new website will provide an alternative view of sector investment that I hope you'll find inspirational. My intent is to point you in the direction of lucrative equity positions and to steer you away from calamitous losers.
As a reminder, there's never any excuse for not contacting a registered, professional financial advisor before making any investment decision. Please read my disclaimer before browsing this site any further.
Thaumaturgical stock analysis is singularly unique to me. I began this voyage just over a year ago and have experienced substantial gains in my portfolio when applying this process optimally. Interpretive analysis on the back-end requires refinement, minimization of error and a genuinely focused effort.
I hope you'll come by frequently to visit Scrying Biotech as we grow in scope and entertainment value.
Always be well...